CN1852925A - 人源化免疫球蛋白基因座 - Google Patents

人源化免疫球蛋白基因座 Download PDF

Info

Publication number
CN1852925A
CN1852925A CNA2004800261928A CN200480026192A CN1852925A CN 1852925 A CN1852925 A CN 1852925A CN A2004800261928 A CNA2004800261928 A CN A2004800261928A CN 200480026192 A CN200480026192 A CN 200480026192A CN 1852925 A CN1852925 A CN 1852925A
Authority
CN
China
Prior art keywords
gene
sequence
nucleic acid
human
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800261928A
Other languages
English (en)
Chinese (zh)
Inventor
R·比罗
W·范肖滕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Therapeutic Human Polyclonals Inc
Original Assignee
Therapeutic Human Polyclonals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therapeutic Human Polyclonals Inc filed Critical Therapeutic Human Polyclonals Inc
Priority to CN201210390234.2A priority Critical patent/CN103205436B/zh
Publication of CN1852925A publication Critical patent/CN1852925A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/107—Rabbit
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Environmental Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNA2004800261928A 2003-07-15 2004-07-15 人源化免疫球蛋白基因座 Pending CN1852925A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201210390234.2A CN103205436B (zh) 2003-07-15 2004-07-15 人源化免疫球蛋白基因座

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48773303P 2003-07-15 2003-07-15
US60/487,733 2003-07-15

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201210390234.2A Division CN103205436B (zh) 2003-07-15 2004-07-15 人源化免疫球蛋白基因座

Publications (1)

Publication Number Publication Date
CN1852925A true CN1852925A (zh) 2006-10-25

Family

ID=34079388

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2004800261928A Pending CN1852925A (zh) 2003-07-15 2004-07-15 人源化免疫球蛋白基因座
CN201210390234.2A Expired - Lifetime CN103205436B (zh) 2003-07-15 2004-07-15 人源化免疫球蛋白基因座

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201210390234.2A Expired - Lifetime CN103205436B (zh) 2003-07-15 2004-07-15 人源化免疫球蛋白基因座

Country Status (10)

Country Link
US (4) US7585668B2 (enExample)
EP (1) EP1644417B1 (enExample)
JP (2) JP2007537704A (enExample)
CN (2) CN1852925A (enExample)
AU (1) AU2004257292A1 (enExample)
CA (1) CA2532117C (enExample)
ES (1) ES2473596T3 (enExample)
IL (1) IL172885A0 (enExample)
MX (1) MXPA06000562A (enExample)
WO (1) WO2005007696A2 (enExample)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104202971A (zh) * 2012-02-01 2014-12-10 瑞泽恩制药公司 表达包含vl结构域的重链的人源化啮齿动物
CN105188357A (zh) * 2013-03-13 2015-12-23 瑞泽恩制药公司 表达限制的免疫球蛋白轻链库的小鼠
CN105189545A (zh) * 2013-03-13 2015-12-23 瑞泽恩制药公司 常见轻链小鼠
CN106414717A (zh) * 2014-05-02 2017-02-15 凯奥目生物科学株式会社 产生人抗体的细胞
US9969814B2 (en) 2010-02-08 2018-05-15 Regeneron Pharmaceuticals, Inc. Methods for making fully human bispecific antibodies using a common light chain
US10130081B2 (en) 2011-08-05 2018-11-20 Regeneron Pharmaceuticals, Inc. Humanized universal light chain mice
CN109996441A (zh) * 2016-11-04 2019-07-09 瑞泽恩制药公司 具有经工程化的免疫球蛋白λ轻链基因座的非人类动物
CN110540996A (zh) * 2019-08-29 2019-12-06 华中农业大学 一种克氏原螯虾i型溶菌酶gLysi2基因、其编码的gLysi2蛋白及其应用
CN112690250A (zh) * 2008-12-18 2021-04-23 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN1852925A (zh) * 2003-07-15 2006-10-25 人类多克隆治疗公司 人源化免疫球蛋白基因座
EP2029729A2 (en) * 2006-05-31 2009-03-04 Genzyme Corporation Methods of using anti-thymocyte globulin and related agents
SG174053A1 (en) * 2006-09-01 2011-09-29 Therapeutic Human Polyclonals Inc Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
US20090053210A1 (en) * 2006-09-01 2009-02-26 Roland Buelow Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
KR102096731B1 (ko) * 2007-06-01 2020-04-02 오픈 모노클로날 테크놀로지, 인코포레이티드 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
JP5588866B2 (ja) * 2007-08-10 2014-09-10 メダレックス エル．エル．シー． Ｈｃｏ３２およびｈｃｏ２７、ならびに関連実施例
WO2009023800A1 (en) * 2007-08-14 2009-02-19 Origen Therapeutics Transgenic chickens with an inactivated endogenous gene locus
EP2108696A1 (en) * 2008-04-10 2009-10-14 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Cis-acting diversification activator and method for selective diversification of nucleic acids
CN102638971B (zh) * 2009-07-08 2015-10-07 科马布有限公司 动物模型及治疗分子
AU2010282508B2 (en) 2009-08-13 2015-05-28 Crystal Bioscience Inc. Transgenic animal for production of antibodies having minimal CDRs
US8865462B2 (en) 2010-01-20 2014-10-21 Crystal Bioscience Inc. Sustained culture of avian gonocytes
US10143186B2 (en) 2010-02-08 2018-12-04 Regeneron Pharmaceuticals, Inc. Common light chain mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
KR101830020B1 (ko) * 2010-03-31 2018-02-19 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작
SG10201504568YA (en) 2010-06-22 2015-07-30 Regeneron Pharma Hybrid light chain mice
EP3960865A1 (en) 2010-08-02 2022-03-02 Regeneron Pharmaceuticals, Inc. Mice that make binding proteins comprising vl domains
CN102250239B (zh) * 2011-06-13 2013-04-17 中国农业科学院哈尔滨兽医研究所 一种与兔出血症病毒vp60蛋白相结合的蛋白及其应用
BR112014006390A2 (pt) * 2011-09-19 2017-03-28 Kymab Ltd anticorpos, domínios variáveis e cadeias feitos especialmente para uso humano
HRP20220253T1 (hr) 2011-10-17 2022-04-29 Regeneron Pharmaceuticals, Inc. Miševi s ograničenim teškim lancem imunoglobulina
ME03477B (me) 2011-12-20 2020-01-20 Regeneron Pharma Miševi sa humanizovanim lakim lancem
HK1200849A1 (en) 2011-12-22 2015-08-14 F. Hoffmann-La Roche Ag Full length antibody display system for eukaryotic cells and its use
SMT201800395T1 (it) 2012-03-16 2018-09-13 Regeneron Pharma Anticorpi a catena leggera ingegnerizzati con istidina e roditori modificati geneticamente per la generazione degli stessi
PT2825037T (pt) 2012-03-16 2019-08-07 Regeneron Pharma Animais não humanos que expressam sequências de imunoglobulinas sensíveis ao ph
KR102484480B1 (ko) 2012-06-12 2023-01-04 리제너론 파마슈티칼스 인코포레이티드 제한된 면역글로불린 중쇄 유전자좌를 가지는 인간화된 비-인간 동물
WO2014022853A1 (en) 2012-08-03 2014-02-06 Sanford Applied Biosciences, L.L.C. Complex chromosome engineering for production of human antibodies in transgenic animals
LT2840892T (lt) 2013-02-20 2018-07-25 Regeneron Pharmaceuticals, Inc. Nežmogaus tipo gyvūnai su modifikuotomis imunoglobulino sunkiųjų grandinių sekomis
TW201532513A (zh) * 2014-01-10 2015-09-01 Alfur Fu-Hsin Hung 能產生比小鼠ＩgＥ量高出許多的人源化ＩgＥ之基因轉殖動物
BR112016021679A2 (pt) 2014-03-21 2018-12-04 Regeneron Pharmaceuticals, Inc. proteína de ligação ao antígeno, métodos de produção de uma proteína de ligação ao antígeno e de identificação de uma ou mais proteínas de ligação ao antígeno, hibridoma, ácido nucleico, célula, e, animal não humano geneticamente modificado.
SG10201808225TA (en) 2014-03-21 2018-10-30 Regeneron Pharma Non-human animals that make single domain binding proteins
HK1250038A1 (zh) 2015-03-19 2018-11-23 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
EP3367786A1 (en) * 2015-10-29 2018-09-05 H. Hoffnabb-La Roche Ag Transgenic rabbit with common light chain
CN110149809B (zh) 2016-12-05 2023-04-14 皇家飞利浦有限公司 无线功率传输系统中的异物检测
SG10202109874VA (en) 2017-01-19 2021-10-28 Open Monoclonal Tech Inc Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
WO2019129677A1 (en) 2017-12-29 2019-07-04 F. Hoffmann-La Roche Ag Anti-vegf antibodies and methods of use
US20210000088A1 (en) * 2018-03-21 2021-01-07 Crystal Bioscience Inc. Transgenic chicken that produces human antibodies
EP3990492A1 (en) 2019-06-27 2022-05-04 F. Hoffmann-La Roche AG Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
AR119382A1 (es) 2019-07-12 2021-12-15 Hoffmann La Roche Anticuerpos de pre-direccionamiento y métodos de uso
AR119393A1 (es) 2019-07-15 2021-12-15 Hoffmann La Roche Anticuerpos que se unen a nkg2d
KR20220116490A (ko) * 2019-12-18 2022-08-23 브리스톨-마이어스 스큅 컴퍼니 공통 리더 서열을 갖는 bcr 트랜스제닉 마우스
CR20240246A (es) 2021-12-20 2024-07-19 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
CN114854901B (zh) * 2022-06-22 2025-11-07 华南农业大学 与苦瓜全雌性状共分离的分子标记、引物及其应用
WO2024261013A1 (en) 2023-06-21 2024-12-26 F. Hoffmann-La Roche Ag Combination therapy with fap-targeted lymphotoxin beta receptor agonists

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE175234T1 (de) 1990-07-10 1999-01-15 Nippon Kokan Kk Geflügelspezifischen immunglobulin g produzierende hybridomas
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
EP0583980A1 (en) 1992-08-20 1994-02-23 Eli Lilly And Company Method for generating monoclonal antibodies from rabbits
WO1997016537A1 (en) 1995-10-30 1997-05-09 Spectral Diagnostics, Inc. Stable chicken b-cell line and method of use thereof
DK1151010T3 (da) 1999-02-05 2006-01-09 Therapeutic Human Polyclonals Humane polyklonale antistoffer fra antigene ikke-humane dyr
CA2375441A1 (en) 1999-06-04 2000-12-14 Tranxenogen, Inc. Methods for manipulating the avian genome
WO2001019394A2 (en) 1999-09-15 2001-03-22 Therapeutic Human Polyclonals, Inc. Immunotherapy with substantially human polyclonal antibody preparations purified from genetically engineered birds
WO2002012437A2 (en) * 2000-08-03 2002-02-14 Schooten Wim Van Production of humanized antibodies in transgenic animals
AU2003261096B2 (en) 2002-06-26 2008-10-02 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Gene regulation in transgenic animals using a transposon-based vector
CN1852925A (zh) * 2003-07-15 2006-10-25 人类多克隆治疗公司 人源化免疫球蛋白基因座
US20100286488A1 (en) 2004-08-27 2010-11-11 Moshe Cohen Method and system for using a mobile device as a portable personal terminal for medical information
US20110077965A1 (en) 2009-09-25 2011-03-31 Cerner Innovation, Inc. Processing event information of various sources
US20120306653A1 (en) 2011-06-02 2012-12-06 Nokia Siemens Networks Oy Medical sensor
US20130021154A1 (en) 2011-07-21 2013-01-24 Solomon Clifford T Medical parameters notification system

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112690250A (zh) * 2008-12-18 2021-04-23 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途
US9969814B2 (en) 2010-02-08 2018-05-15 Regeneron Pharmaceuticals, Inc. Methods for making fully human bispecific antibodies using a common light chain
US10130081B2 (en) 2011-08-05 2018-11-20 Regeneron Pharmaceuticals, Inc. Humanized universal light chain mice
US11357217B2 (en) 2011-08-05 2022-06-14 Regeneron Pharmaceuticals, Inc. Humanized universal light chain mice
CN106117364B (zh) * 2012-02-01 2021-08-31 瑞泽恩制药公司 表达包含vl结构域的重链的人源化啮齿动物的制备方法
CN104202971B (zh) * 2012-02-01 2016-07-06 瑞泽恩制药公司 表达包含vl结构域的重链的人源化啮齿动物的制备方法
CN106117364A (zh) * 2012-02-01 2016-11-16 瑞泽恩制药公司 表达包含vl结构域的重链的人源化啮齿动物的制备方法
CN104202971A (zh) * 2012-02-01 2014-12-10 瑞泽恩制药公司 表达包含vl结构域的重链的人源化啮齿动物
CN105188357B (zh) * 2013-03-13 2018-04-24 瑞泽恩制药公司 表达限制的免疫球蛋白轻链库的小鼠
CN105189545A (zh) * 2013-03-13 2015-12-23 瑞泽恩制药公司 常见轻链小鼠
CN105188357A (zh) * 2013-03-13 2015-12-23 瑞泽恩制药公司 表达限制的免疫球蛋白轻链库的小鼠
CN106414717A (zh) * 2014-05-02 2017-02-15 凯奥目生物科学株式会社 产生人抗体的细胞
CN109996441A (zh) * 2016-11-04 2019-07-09 瑞泽恩制药公司 具有经工程化的免疫球蛋白λ轻链基因座的非人类动物
CN110540996A (zh) * 2019-08-29 2019-12-06 华中农业大学 一种克氏原螯虾i型溶菌酶gLysi2基因、其编码的gLysi2蛋白及其应用

Also Published As

Publication number Publication date
CN103205436B (zh) 2016-05-25
CA2532117A1 (en) 2005-01-27
US20130189774A1 (en) 2013-07-25
CN103205436A (zh) 2013-07-17
US20100205682A1 (en) 2010-08-12
JP6017763B2 (ja) 2016-11-02
US20060026696A1 (en) 2006-02-02
US8410333B2 (en) 2013-04-02
US7585668B2 (en) 2009-09-08
WO2005007696A3 (en) 2005-11-03
CA2532117C (en) 2012-07-10
MXPA06000562A (es) 2006-03-30
JP2011182801A (ja) 2011-09-22
US8652842B2 (en) 2014-02-18
EP1644417B1 (en) 2014-04-30
EP1644417A2 (en) 2006-04-12
USRE47131E1 (en) 2018-11-20
AU2004257292A1 (en) 2005-01-27
JP2007537704A (ja) 2007-12-27
WO2005007696A2 (en) 2005-01-27
ES2473596T3 (es) 2014-07-07
IL172885A0 (en) 2006-06-11

Similar Documents

Publication Publication Date Title
AU2018223041B2 (en) Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
CN1852925A (zh) 人源化免疫球蛋白基因座
KR102266274B1 (ko) 제한된 면역글로불린 중쇄 유전자좌를 가지는 인간화된 비-인간 동물
KR102719587B1 (ko) 아데노-관련 바이러스 생산을 위한 포유동물 세포
KR102630357B1 (ko) 단백질 발현이 어려운 다중-부위 ssi 세포
AU2023214237A1 (en) Modified polynucleotides for the production of biologics and proteins associated with human disease
AU2019316556B2 (en) Methods for assessing the risk of developing progressive multifocal leukoencephalopathy caused by john cunningham virus by genetic testing
AU2016364667A1 (en) Materials and methods for treatment of Alpha-1 antitrypsin deficiency
EP1165784A2 (en) Nucleic acids including open reading frames encoding polypeptides; "orfx"
JP2003088388A (ja) 新規な全長ｃＤＮＡ
JP2003135075A (ja) 新規な全長ｃＤＮＡ
AU2017289886A1 (en) Engineered parasites for delivering protein to the central nervous system (CNS)
WO1995014772A1 (en) Gene signature
HUE034321T2 (en) Restricted immunoglobulin heavy chain mice
KR20190120170A (ko) Vhh-함유 중쇄 항체 및 이의 생산
KR102777514B1 (ko) 다중 중쇄 면역글로불린 유전자좌를 갖는 트랜스제닉 설치류 기원의 인간 항체
KR20110110030A (ko) 뇌종양의 재발 가능성 및 생존 예후 예측용 조성물 및 이를 포함하는 키트
KR101978399B1 (ko) 자궁내막증에 대한 진단 마커로서의 돌연변이 유전자 및 이의 용도
JP2002017375A (ja) 全長ｃＤＮＡ合成用プライマー、およびその用途
KR102364720B1 (ko) 교모세포종 진단용 바이오마커 조성물

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20061025